Study on ZN-c3 for Adults with Advanced Colorectal Cancer

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05743036

Provider View

This clinical trial is testing a new treatment combination involving ZN-c3, encorafenib, and cetuximab to see if it is safe and beneficial for adults with advanced colorectal cancer that has a specific BRAF V600E mutation and has not responded to one or two previous treatments.

Patient Parameters

Program Overview

The aim of this study is to determine if a new combination of drugs, including ZN-c3, encorafenib, and cetuximab, is safe and can provide clinical benefits for adults with advanced colorectal cancer that has a specific genetic mutation (BRAF V600E) and has not improved with one or two prior treatments.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced Stage IV colorectal cancer.
  • Have a specific genetic mutation called BRAF V600E in the cancer cells.
  • Have at least one tumor that can be measured using standard criteria.
  • The cancer must have worsened after one or two previous treatments for advanced cancer.
  • Have good bone marrow function.
  • Have good liver and kidney function.

Exclusion Criteria

  • Cancer has worsened during the screening period.
  • Have cancer that has spread to the membranes surrounding the brain and spinal cord.
  • Have symptoms from cancer that has spread to the brain.
  • Have acute or chronic inflammation of the pancreas.
  • Cannot swallow or absorb oral medications.
  • Have serious heart diseases.
  • Have active lung inflammation not caused by infection.
  • Have an active and uncontrolled bacterial or viral infection within two weeks before starting the study treatment.
  • Have HIV.
  • Have active hepatitis B or C infection.
  • Have another type of cancer within the last two years.
  • Have had a tissue or organ transplant.
  • Are pregnant or breastfeeding, or women who could become pregnant and have a positive pregnancy test within 14 days before joining the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.